ORKAMBI Trademark

Trademark Overview

On Thursday, January 30, 2014, a trademark application was filed for ORKAMBI with the United States Patent and Trademark Office. The USPTO has given the ORKAMBI trademark a serial number of 86179790. The federal status of this trademark filing is REGISTERED AND RENEWED as of Monday, August 4, 2025. This trademark is owned by Vertex Pharmaceuticals Incorporated. The ORKAMBI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cystic fibrosis
orkambi

General Information

Serial Number86179790
Word MarkORKAMBI
Filing DateThursday, January 30, 2014
Status800 - REGISTERED AND RENEWED
Status DateMonday, August 4, 2025
Registration Number4822946
Registration DateTuesday, September 29, 2015
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 17, 2014

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cystic fibrosis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 11, 2014
Primary Code005
First Use Anywhere DateWednesday, July 8, 2015
First Use In Commerce DateWednesday, July 8, 2015

Trademark Owner History

Party NameVertex Pharmaceuticals Incorporated
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBoston, MA 02210
Party NameVertex Pharmaceuticals Incorporated
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoston, MA 02210
Party NameVertex Pharmaceuticals Incorporated
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02210

Trademark Events

Event DateEvent Description
Monday, February 3, 2014NEW APPLICATION ENTERED
Tuesday, February 11, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 9, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 28, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 17, 2014PUBLISHED FOR OPPOSITION
Tuesday, June 17, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 6, 2014ASSIGNED TO EXAMINER
Tuesday, August 12, 2014NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Saturday, January 24, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 3, 2015USE AMENDMENT FILED
Wednesday, August 26, 2015STATEMENT OF USE PROCESSING COMPLETE
Thursday, August 27, 2015ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, August 28, 2015NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, September 29, 2015REGISTERED-PRINCIPAL REGISTER
Thursday, January 22, 2015SOU TEAS EXTENSION RECEIVED
Thursday, January 22, 2015SOU EXTENSION 1 FILED
Thursday, January 22, 2015SOU EXTENSION 1 GRANTED
Monday, August 3, 2015TEAS STATEMENT OF USE RECEIVED
Monday, August 17, 2015CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, February 10, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, September 29, 2024COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Monday, March 17, 2025TEAS SECTION 8 & 9 RECEIVED
Monday, August 4, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, August 4, 2025REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Monday, August 4, 2025REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Tuesday, September 29, 2020COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, August 23, 2021TEAS SECTION 8 & 15 RECEIVED
Tuesday, November 23, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, November 23, 2021REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Tuesday, November 23, 2021NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Monday, August 4, 2025NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

Related Keywords

orkambi fibrosis cystic treatment preparations pharmaceutical